loading page

COVID-19-associated mucormycosis involving the maxilla
  • +3
  • Mahboube Hasheminasab,
  • mojtaba salehi karizmeh,
  • reza sharifi,
  • Majid Beshkar,
  • Narges Matloubi,
  • Amirali Asadi
Mahboube Hasheminasab
Tehran University of Medical Sciences

Corresponding Author:mahboube.hasheminasab@gmail.com

Author Profile
mojtaba salehi karizmeh
Tehran University of Medical Sciences
Author Profile
reza sharifi
Tehran University of Medical Sciences
Author Profile
Majid Beshkar
Tehran University of Medical Sciences
Author Profile
Narges Matloubi
Tehran University of Medical Sciences
Author Profile
Amirali Asadi
Tehran University of Medical Sciences
Author Profile

Abstract

It is important to increase the awareness of head and neck surgeons about the recent surge of craniofacial mucormycosis in COVID-19 patients, because early diagnosis and treatment are essential to improve the outcomes. Here, we describe clinical features, treatment protocols, and outcomes of treatment in 8 patients with COVID-19-associated mucormycosis
28 Jan 2022Submitted to Clinical Case Reports
18 Mar 2022Submission Checks Completed
18 Mar 2022Assigned to Editor
03 Apr 2022Reviewer(s) Assigned
25 Apr 2022Review(s) Completed, Editorial Evaluation Pending
25 Apr 2022Editorial Decision: Revise Minor
05 May 20221st Revision Received
13 May 2022Submission Checks Completed
13 May 2022Assigned to Editor
13 May 2022Review(s) Completed, Editorial Evaluation Pending
13 May 2022Editorial Decision: Accept
Aug 2022Published in Clinical Case Reports volume 10 issue 8. 10.1002/ccr3.6165